Redeye comments on Camurus' Q4 report 2025, which was below our estimates due to a large sequential sales decline of Buvidal sales in Europe, explained largely by an inventory repurchase. However, the underlying operations demonstrate growth and an increasing number of patients on treatment. After the share retracement following the report, we believe it is undervalued.
LÄS MER
